EGFR and breast cancer: However, we found that HER-1- and HER-4-based dimer formation is differently stimulated by trastuzumab and pertuzumab and that their combinatorial use produces greater reduction of all HER-1- and HER-4-based dimers, thus generating a better clinical effect in breast cancer cells.